Skip to content

EBIT at other companies

EyePoint, Inc.
 logo
EyePoint, Inc. EYPT
-$87.23M-78.6%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
-$93.34M-46.0%
Eli Lilly logo
Eli LillyLLY
Merck & Co. logo
Merck & Co.MRK
Amgen logo
AmgenAMGN
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN

Other financials

Income statement

See full
Operating income-$11.8M-14.3%
Net income-$10.9M-6.5%
EPS (diluted)-$0.46+81.7%

Balance sheet

See full
Cash & equivalents$34.4M-65.9%
Total debt$1.4M
Total equity$68.6M+7.3%
Total assets$109.8M+6.5%

Cash flow

See full
Operating cash flow-$11.6M-55.6%
CapEx$17.0K
Free cash flow-$7.1M

Valuation

See full
Market cap$96.83M+136%
Enterprise value$63.82M

Returns & leverage

See full
Return on equity-66.6%
Debt / equity
Current ratio12.2×-2.1×

Where this comes from

Calculated from KLRS’s reported figures.

The official record: KLRS’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about KLRS's ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is KLRS's EBIT?
KLRS (KLRS) reported EBIT of -$11.83M in Q1 2026.
How has KLRS's EBIT changed year-over-year?
KLRS's EBIT decreased by 14.3% year-over-year, from -$10.35M to -$11.83M.
What is the long-term trend for KLRS's EBIT?
Over 3 years (2021 to 2025), KLRS's EBIT has grown at a -35.2% compound annual growth rate (CAGR), from -$169.82M to -$46.15M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.